CRL-1897 UACC 812 人乳腺导管瘤细胞_详细资料

产品信息

品牌其他品牌供货周期一周应用领域医疗/卫生,化学品检测,生物产业,石油/化工

CRL-1897 UACC 812 人乳腺导管瘤细胞
ATCC^® Number: CRL-1897™
Designations: UACC-812
Depositors: A Liebovitz, J Trent
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens （human）
Morphology: epithelial

Source: Organ: mammary gland; breast
Disease: ductal carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
CRL-1897 UACC 812 人乳腺导管瘤细胞
Restrictions: The breast carcinoma UACC-812 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona. The cells are distributed for research purposes only. The University of Arizona has released the line subject to the following: 1. UACC-812 or their products MUST NOT BE DISTRIBUTED to third parties. Commercial interests are the exclusive property of the University of Arizona. 2. Any proposed commercial use of these cells must first be negotiated with the Director of the Arizona Cancer Center, University of Arizona, 1501 N. Campbell Avenue, Tucson, Arizona 85724. ephone （602） 626-7925, （602） 626-2284. 3. In all papers reporting any use of these of these cells or derived products, a direct reference will be made to the original publication given above.
Isolation: Isolation date: 1986
Receptors: estrogen receptor
progesterone receptor
Cytogenetic Analysis: range = 58 to 64; abnormal banding region in 3p
Age: 43 years
Gender: female
Comments: This cell line was established by A. Liebovitz and associates in 1986 from breast tissue removed at mastectomy to remove a ductal carcinoma （stage II, grade IV）.
Prior to surgery, the patient had received extensive chemotherapy.
The cells exhibit a 15 fold amplification of the HER-2/neu oncogene sequence.
They are negative for estrogen receptors, progesterone receptors and P glycoprotein.
Propagation: ATCC complete growth medium: Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 20 ng/ml human EGF and 20% fetal bovine serum
Atmosphere: air,
Temperature: 37.0°C
Growth conditions: The cells grow very slowly, and growth is enhanced by using 20% fetal bovine serum and adding epidermal growth factor （20 ng/ml） to the medium.
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% （w/v） Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed （usually within 5 to 15 minutes）.
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% （v/v） DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 100 hrs
Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2008
recommended serum:ATCC 30-2020
purified DNA:ATCC 45534
purified DNA:ATCC 45535
purified DNA:ATCC CRL-1897D
References: 22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.
26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877
CRL-1897
CRL-1897
CRL-1897

您可能感兴趣的产品